Orakl Oncology, a French startup, is leveraging artificial intelligence to innovate cancer drug trials by integrating patient-specific data and organoid models, aiming to overcome the high failure rate of new drug compounds in clinical trials. With significant funding and a focus on colorectal and pancreatic cancers, Orakl's approach combines data science and biological research to personalize and enhance cancer treatment, addressing the complexities of biological systems and regulatory challenges.